• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    NovoCure (NVCR) Could Be 71% Undervalued Following Its Pancreatic Cancer Trial Collaboration

    Simply Wall St·10/29/2026 04:56:17
    Listen to the news

    NovoCure (NVCR) has put fresh attention on its pipeline after announcing a clinical trial collaboration with Verastem Oncology to test Tumor Treating Fields alongside chemotherapy and the KRAS G12D inhibitor VS-7375 in locally advanced pancreatic cancer.

    NovoCure’s clinical update lands after a mixed run in the market, with the share price down 10.5% over the past month and 7% over 90 days, yet still showing an 8% year to date share price return and a 5.1% total shareholder return over one year.

    Scan how NovoCure’s pancreatic cancer push compares with other potential breakout plays in healthcare by reviewing the hand picked 36 healthcare AI stocks.

    The share price reset has reopened the debate. Does NovoCure’s current valuation still leave enough upside potential to justify the clinical and earnings risk investors are taking?

    Most Popular Narrative: 71% Undervalued

    Compared with NovoCure’s last close of $14.17, the most followed narrative estimates fair value at $48.80. This frames the current cancer trial news within a much broader discussion about long term earnings power and cash generation.

    Progress toward positive adjusted EBITDA, with Q2 2026 at US$11 million and guidance for full year 2026 between breakeven and US$15 million, combined with a 78% gross margin and a US$441 million cash and investment balance including US$200 million of debt, gives NovoCure room to self fund device launches and mix shift without relying on external capital, which can influence net margin trajectory and per share earnings over time.

    See why 5 investors see NovoCure as 71% undervalued.

    Result: Fair Value of $48.80 (UNDERVALUED)

    Still, the NovoCure narrative can break if TRIDENT style trial disappointments keep denting confidence, or if ongoing GAAP losses and legal costs erode its cash cushion.

    Find out about the key risks to this NovoCure narrative.

    Next Steps

    Sentiment around NovoCure is split, which is exactly when fresh data can matter most for your own judgment. Move quickly, review the upside factors, and weigh the 3 key rewards.

    Looking for more NovoCure sized ideas?

    If NovoCure has sharpened your focus, do not stop here. Broaden your watchlist with fresh setups that could suit different risk profiles and return goals.